ReviewFrontiers in oncology2023

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations.

Lucía Vázquez-Montero et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.